64
Participants
Start Date
December 16, 2022
Primary Completion Date
October 8, 2026
Study Completion Date
October 8, 2026
Multiple ascending doses of QRL-201
Multiple ascending doses of QRL-201 will be intrathecally administered to individuals with sporadic ALS.
Multiple ascending doses of Placebo
Multiple ascending doses of placebo comparator will be intrathecally administered to individuals with sporadic ALS.
QRL-201
QRL-201 will be intrathecally administered to individuals with C9orf72 ALS.
Placebo
Placebo comparator will be intrathecally administered to individuals with C9orf72 ALS.
Charité Research Organisation, Berlin
Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE), Bonn
Universitätsklinikum Ulm, Ulm
Universitaire Ziekenhuizen Leuven (UZ Leuven), Leuven
University of Calgary, Calgary
University of Alberta, Edmonton
Sunnybrook Health Science Centre, Toronto
CHUM - Hopital Notre-Dame, Montreal
Montreal Neurological Institute-Hospital, Montreal
University Hospital Schleswig-Holstein (UKSH) Campus Lübeck, Department for Neurology/ Precision Neurology, Lübeck
Universitair Medisch Centrum Utrecht, Utrecht
St James's Hospital, Dublin
The University of Sheffield, Royal Hallamshire Hospital, Sheffield
Kings College Hospital NHS Foundation Trust, London
National Hospital for Neurology and Neurosurgery, London
QurAlis Corporation
INDUSTRY